Invesco Ltd. Ngm Biopharmaceuticals Inc Transaction History

Invesco Ltd.

  • $460 Billion
  • Q2 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
SELL
$1.17 - $1.92 $892 - $1,464
-763 Reduced 5.57%
12,936 $20,000
Q4 2023

Feb 12, 2024
SELL
$0.6 - $1.31 $8,893 - $19,418
-14,823 Reduced 51.97%
13,699 $11,000
Q3 2023

Nov 13, 2023
BUY
$1.05 - $3.37 $5,868 - $18,834
5,589 Added 24.37%
28,522 $30,000
Q2 2023

Aug 11, 2023
BUY
$2.44 - $4.53 $4,135 - $7,678
1,695 Added 7.98%
22,933 $59,000
Q1 2023

May 12, 2023
BUY
$3.72 - $5.4 $6,669 - $9,682
1,793 Added 9.22%
21,238 $86,000
Q4 2022

Feb 13, 2023
SELL
$3.41 - $12.93 $144,781 - $548,981
-42,458 Reduced 68.59%
19,445 $97,000
Q3 2022

Nov 14, 2022
BUY
$12.59 - $17.67 $99,750 - $139,999
7,923 Added 14.68%
61,903 $809,000
Q2 2022

Aug 15, 2022
SELL
$10.58 - $17.5 $13,309 - $22,015
-1,258 Reduced 2.28%
53,980 $693,000
Q1 2022

May 16, 2022
BUY
$13.81 - $18.6 $45,752 - $61,621
3,313 Added 6.38%
55,238 $842,000
Q4 2021

Feb 14, 2022
BUY
$17.26 - $22.02 $47,119 - $60,114
2,730 Added 5.55%
51,925 $920,000
Q3 2021

Nov 15, 2021
BUY
$20.15 - $26.19 $689,210 - $895,802
34,204 Added 228.16%
49,195 $1.03 Million
Q2 2021

Aug 17, 2021
SELL
$15.06 - $30.03 $297,811 - $593,843
-19,775 Reduced 56.88%
14,991 $296,000
Q1 2021

May 17, 2021
SELL
$24.99 - $31.93 $1.06 Million - $1.35 Million
-42,412 Reduced 54.95%
34,766 $1.01 Million
Q4 2020

Feb 16, 2021
BUY
$16.21 - $31.44 $537,539 - $1.04 Million
33,161 Added 75.34%
77,178 $2.34 Million
Q3 2020

Nov 16, 2020
BUY
$15.59 - $19.97 $96,424 - $123,514
6,185 Added 16.35%
44,017 $700,000
Q2 2020

Aug 14, 2020
BUY
$11.97 - $23.47 $452,849 - $887,917
37,832 New
37,832 $747,000

Others Institutions Holding NGM

# of Institutions
5
Shares Held
2.6M
Call Options Held
300
Put Options Held
0
View Full List

About NGM BIOPHARMACEUTICALS INC

NGM Quotes by TradingView
  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email